PD-1/PD-1L interaction inhibitors described in Affirma Biotech patent
Cancer Affirma Biotech SL has disclosed new programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors potentially useful for the treatment of cancer, bacterial, fungal and viral infections. BioWorld Science Cancer …